SignalFDA/Bio
Innovent reports cancer drug results in breast, lung, pancreatic tumors
Cancer drug results reported across breast, lung, and pancreatic tumors.
Context
What happened: Innovent Biologics (IVBIY)(IVBXF) reported encouraging clinical trial results for two experimental cancer drugs, presented at the European conference.
Key numbers: 95% tumor response rate in patients with advanced breast cancer.
Why it matters: The results include evidence of activity against several difficult-to-treat tumors, including breast, lung, and pancreatic tumors.
What changed
Innovent Biologics (IVBIY)(IVBXF) reported encouraging clinical trial results for two experimental cancer drugs, presented at the European conference.
Why it matters
The results include evidence of activity against several difficult-to-treat tumors, including breast, lung, and pancreatic tumors.